Selected biofunctions, canonical pathways, and upstream regulators predicted to be significantly activated or inhibited according to the corresponding deregulated genes between CD22+CD25− and CD22lowCD25+ normal bone marrow B lymphocytes and between the Waldenström clone vs each normal B-cell subset
| Enrichment analysis . | CD22lowCD25+ vs CD22+CD25− . | Waldenström clone vs CD22+CD25− B cells . | Waldenström clone vs CD22lowCD25+ B cells . |
|---|---|---|---|
| Biofunctions | |||
| Cellular development, cellular growth and proliferation | Activated (26 genes; P = 9.7E-07) | Activated (39 genes; P = 2.8E-07) | Inhibited (18 genes; P = 3.6E-02) |
| Cell death and survival | Activated (57 genes; P = 3.7E-04) | Activated (46 genes; P = 2.7E-04) | — |
| Humoral immune response, IgG protein synthesis | Inhibited (9 genes; P = 2.0E-04) | Inhibited (13 genes; P = 7.2E-05) | — |
| Canonical pathways | |||
| D-myo-inositol (1,3,4,5,6)-tetrakisphosphate biosynthesis | Activated (6 genes; P = 6.4E-04) | Activated (8 genes; P = 5.8E-04) | — |
| 3-phosphoinositide biosynthesis | Activated (7 genes; P = 3.3E-04) | Activated (8 genes; P = 2.4E-03) | — |
| Upstream regulators | |||
| BCR | Activated (8 genes; P = 1.4E-06) | Activated (12 genes; P = 2.6E-08) | — |
| CD40 | Activated (10 genes; P = 1.2E-06) | Activated (13 genes; P = 1.5E-06) | — |
| INFα | Activated (12 genes; P = 5.8E-06) | Activated (14 genes; P = 1.6E-04) | — |
| INFγ | Activated (19 genes; P = 2.2E-03) | Activated (40 genes; P = 3.8E-07) | Inhibited (9 genes; P = 1.2E-03) |
| miRNA-92a | Inhibited (20 genes; P = 9.3E-04) | Inhibited (38 genes; P = 2.8E-06) | — |
| miRNA-181a | Inhibited (24 genes; P = 9.8 E-04) | Inhibited (49 genes; P = 1.3E-07) | — |
| TP53 | Activated (23 genes; P = 3.7E-04) | Activated (36 genes; P = 6.0E-05) | — |
| Enrichment analysis . | CD22lowCD25+ vs CD22+CD25− . | Waldenström clone vs CD22+CD25− B cells . | Waldenström clone vs CD22lowCD25+ B cells . |
|---|---|---|---|
| Biofunctions | |||
| Cellular development, cellular growth and proliferation | Activated (26 genes; P = 9.7E-07) | Activated (39 genes; P = 2.8E-07) | Inhibited (18 genes; P = 3.6E-02) |
| Cell death and survival | Activated (57 genes; P = 3.7E-04) | Activated (46 genes; P = 2.7E-04) | — |
| Humoral immune response, IgG protein synthesis | Inhibited (9 genes; P = 2.0E-04) | Inhibited (13 genes; P = 7.2E-05) | — |
| Canonical pathways | |||
| D-myo-inositol (1,3,4,5,6)-tetrakisphosphate biosynthesis | Activated (6 genes; P = 6.4E-04) | Activated (8 genes; P = 5.8E-04) | — |
| 3-phosphoinositide biosynthesis | Activated (7 genes; P = 3.3E-04) | Activated (8 genes; P = 2.4E-03) | — |
| Upstream regulators | |||
| BCR | Activated (8 genes; P = 1.4E-06) | Activated (12 genes; P = 2.6E-08) | — |
| CD40 | Activated (10 genes; P = 1.2E-06) | Activated (13 genes; P = 1.5E-06) | — |
| INFα | Activated (12 genes; P = 5.8E-06) | Activated (14 genes; P = 1.6E-04) | — |
| INFγ | Activated (19 genes; P = 2.2E-03) | Activated (40 genes; P = 3.8E-07) | Inhibited (9 genes; P = 1.2E-03) |
| miRNA-92a | Inhibited (20 genes; P = 9.3E-04) | Inhibited (38 genes; P = 2.8E-06) | — |
| miRNA-181a | Inhibited (24 genes; P = 9.8 E-04) | Inhibited (49 genes; P = 1.3E-07) | — |
| TP53 | Activated (23 genes; P = 3.7E-04) | Activated (36 genes; P = 6.0E-05) | — |
A detailed list of genes under each selected biofunction, canonical pathway, and upstream regulator and their corresponding expression status is available in supplemental Table 5.